Warren C. Lau

Mast Therapeutics, Inc. is a biopharmaceutical company, which engages in developing novel therapies for serious or life-threatening diseases with significant unmet needs. It leveraging Molecular Adhesion and Sealant Technology, platform, derived from over two decades of clinical, nonclinical, and manufacturing experience with purified and non-purified poloxamers to develop vepoloxamer, which also known as MST-188. The company was founded by Warren C. Lau in December 1995 and is headquartered in San Diego, CA.

HoustonPharma, Inc. develops pharmaceutical products and technologies. It develops oncolytic virus technologies for the treatment of cancer, including ovarian cancer, glioblastoma, and multiple myeloma. The company is headquartered in Malvern, PA.

Photovoltaic Solar Cells, Inc. is a development stage company. It engages in identifying, investigating and if warranted, acquiring companies. The company was founded by Lawrence F. Curtin on March 28, 2007 and is headquartered in New York, NY.

Nexus Biopharma, Inc. is a preclinical stage biotechnology company, which engages in the research and development of new therapies and intellectual property for treating obesity and type 2 diabetes. The company was founded by Warren C. Lau on July 17, 2007 and is headquartered in Houston. TX.

Part of Ngen, Inc., Synthetic Genetics is an American company that provides a broad line of modified obligonucleotides, including research probes to the research market. The company was founded by Richard H. Tullis. Synthetic Genetics was acquired by Epoch Biosciences, Inc., a subsidiary of Ngen, Inc. from Immune Complex Corp. on November 21, 2000 for $3.10 million.

Opexa Therapeutics, Inc. engages as a biopharmaceutical company, which develops personalized immunotherapy with the potential to treat major illnesses including multiple sclerosis and other autoimmune diseases. Its product candidates include Tcelna and OPX-212. The company was founded in March 1991 and is headquartered in The Woodlands, TX.